Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Simard, M. Articles by van Reekum, R. Search for Related Content PubMed Citation Articles by Simard, M. Articles by van Reekum, R. Dementias (General) Cognition

The Acetylcholinesterase Inhibitors for Treatment of Cognitive and Behavioral Symptoms in Dementia With Lewy Bodies

Received September 23, 2002; revised November 26, 2002; accepted January 1, 2003. From the School of Psychology, Laval University, Quebec City, Canada; the Neuropsychiatry Program, Centre for Addiction and Mental Health, Toronto; Department of Psychiatry, University of Toronto; Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care, Toronto, Canada; École de psychologie, Université de Moncton, Moncton, Canada. From the Department of Psychiatry and Kunin-Lunenfeld Applied Research Unit, Baycrest Centre for Geriatric Care; and the Division of Geriatric Psychiatry, Department of Psychiatry, University of Toronto, Toronto, Canada. Address correspondence to Dr. Simard, School of Psychology, Laval University, Quebec City, QC, Canada, G1K 7P4; Martine.Simard{at}psy.ulaval.ca (E-mail).

Dementia with Lewy bodies (DLB) is a common cause of dementia with effects on cognition, mood, behavior, and function. Changes in the acetylcholine system have been reported in brains of patients with DLB, which provides a rationale for trials of acetylcholinesterase inhibitors in DLB. This review includes all English-language publications found via Medline and related to the efficacy and/or safety of these compounds in DLB. Preliminary data suggest that these compounds may be efficacious in DLB and that future randomized clinical trials are strongly needed. Methodological limitations of the existing data include small sample sizes, and the paucity of standardized psychometric measures.

This article has been cited by other articles:

				R. Kurlan, J. Cummings, R. Raman, L. Thal, and For the Alzheimer's Disease Cooperative Study Grou Quetiapine for agitation or psychosis in patients with dementia and parkinsonism Neurology, April 24, 2007; 68(17): 1356 - 1363. [Abstract] [Full Text] [PDF]

				J. A. H. R. Claassen and R. W. M. M. Jansen Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2006; 61(3): 267 - 271. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us